MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with P

Pyrazinamide

Pyrazinamide 500mg tablets

Use with caution

Stability notes for Pyrazinamide 500mg tablets

Moisture sensitive medicine. Store in airtight (sealed) MCA No stability data in MCAs available.

Provenance

This recommendation is based on the products Pyrazinamide 500mg tablets (Morningside Healthcare Ltd).

Suppliers (5) of Pyrazinamide 500mg tablets
Pyrazinamide 500mg tablets (A A H Pharmaceuticals Ltd)
Pyrazinamide 500mg tablets (Alliance Healthcare (Distribution) Ltd)
Pyrazinamide 500mg tablets (Macleods Pharma UK Ltd)
Pyrazinamide 500mg tablets (Morningside Healthcare Ltd)
Zinamide 500mg tablets (Genus Pharmaceuticals Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.